Book a Meeting
Creative Biolabs - ADCC+ Antibody

Anti-CD25 Antibody, ADCC Enchanced (BioBet-CB-013LX) (CAT#: BioBet-CB-013LX) Datasheet

Target
CD25
Isotype
IgG1
Description
Anti-CD25 Antibody, ADCC Enchanced (BioBet-CB-013LX) is a glycosylation-modified anti-CD25 therapeutic antibody.
Antibody Indication
Chronic lymphocytic leukemia; follicular lymphoma; some types of non-Hodgkin lymphoma (NHL);some non-cancer related illnesses
Classification
Therapeutic antibody; biobetter

Cooperation Seeking

Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced CD25 antibody. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Official Name
Interleukin-2 receptor subunit alpha
Full Name
Interleukin-2 receptor subunit alpha
Background
CD25, a 55 kD type I transmembrane glycoprotein, has been shown to play roles in lymphocyte differentiation, activation, and proliferation. Many resting memory T cells constitutively express IL2Rα. It functions as the receptor for HTLV-1, resulting in its expression on neoplastic cells in adult T cell lymphoma/leukemia. CD25 (sIL-2R) has been used to track disease progression. Some additional clinical applications include Chagas disease, a disease characterized by a decline of CD25 expression on immune cells, and Multiple sclerosis, in which treatments with mAbs target CD25.
Alternative Names
IL-2-RA; IL2-RA; TAC antigen; p55; CD25
Gene ID
3559
UniProt ID
P01589
Field of research
Cell Biology, Immunology,
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Antibody Isotype
IgG1
Antibody Clone
BioBet-CB-013LX
Host
Human
Species Reactivity
Human
Description
ADCC-Enhanced Anti-Human CD25 (Camidanlumab) Antibody is derived from clone Camidanlumab, which is a Human monoclonal antibody with enhanced ADCC activity. Antibody-dependent cellular cytotoxicity (ADCC) is an important function of antibody. It is a part of the humoral immune response to limit and contain infection. The antibody targets the CD25, and it is intended for the research of Hodgkin lymphoma.
Antibody Indication
Hodgkin lymphoma

Hodgkin lymphoma

Related Products

Anti-CD25 Antibody, Non-Fucosylated (BioBet-303ZP) (CAT#: BioBet-303ZP)
Anti-CD25 Antibody, Highly Galactosylated (BioBet-GA-303ZP) (CAT#: BioBet-GA-303ZP)
Anti-CD25 Antibody, Highly Galactosylated (BioBet-GA-304ZP) (CAT#: BioBet-GA-304ZP)
Anti-CD25 Antibody, On-Target (AES-0622-ZP688) (CAT#: AES-0622-ZP688)
Anti-CD25 Antibody, Recycling (AES-0622-ZP32) (CAT#: AES-0622-ZP32)
Anti-CD25 Antibody, Half-Life Extended (AES-0622-ZP1016) (CAT#: AES-0622-ZP1016)
Anti-CD25 Antibody, Highly Galactosylated (BioBet-GA-305ZP) (CAT#: BioBet-GA-305ZP)
Anti-CD25 Antibody, FcγRIIB Binding Enhanced (AES-0622-ZP360) (CAT#: AES-0622-ZP360)

All products and services are for Research Use Only. Do Not use in humans.

ONLINE INQUIRY

Creative Biolabs has established a team of customer support scientists ready to discuss ADCC/CDC optimization strategies, antibody production, bioinformatics analysis and other molecular biology/biotechnology issues.

  • *
  • *

ISO 9001 Certified - Creative Biolabs Quality Management System.
© 2025 Creative Biolabs. All rights reserved.
Merry Christmas Merry Christmas